The prognosis of patients with relapsed or refractory acute myeloid leukemia (R/R AML) is discouraging with salvage standard approaches. 
Introduction
Despite improvements in chemotherapy over the last years, the majority of adult patients with acute myeloid leukemia (AML) will show primary refractory disease or relapse after achieving complete remission (CR). 1 The prognosis of relapsed/ refractory (R/R) AML patients is particularly poor, but in a subset of patients salvage therapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) was shown to be possibly curative. 2 Whole-genome sequencing of AML has revealed some acquired mutations in such genes as isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) genes, encoding for two enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (αKG) and reduce nicotinamide adenine dinucleotide phosphate (NADP + ) to NADPH. In mutated IDH1 (IDH1 mut ) and IDH2 (IDH2 mut) , NADPH is oxidized to NADP+ and αKG transformed into the oncometabolite D-2-hydroxyglutarate (2HG). When levels of 2HG are increased, they interfere with cellular metabolism and epigenetic regulation and hence contribute to leukemogenesis. Somatic mutations of IDH1 and IDH2 genes are found in 7-14% and 8-19% of AML cases, respectively.
The recent discovery of new mutations in AML has opened the door to targeted agents that are actually in use or under investigation. This is the case for IDH1 mut and IDH2 mut inhibitors for patients with IDH mutations.
Enasidenib was the first inhibitor of IDH2 to be approved by the US Food and Drug Administration (FDA) in August 2017 for R/R AML that carries IDH2 mut . More recently, in July 2018, ivosidenib which inhibits mutated cytosolic IDH1 was also approved for R/R AML. Following this path, there are other IDH1 mut and IDH2 mut inhibitors and their combinations with other therapies under investigation (ie, intensive chemotherapy and hypomethylating agents). 5 Our aim was to perform a systematic review of the literature and to analyze the clinical outcomes reported with IDH1 mut inhibitors and other agents in adult patients with IDH1 mut R/R AML.
Materials and methods

Search strategy and selection of studies
In accordance with the PRISMA guidelines, two independent reviewers (JMV and PM) conducted this systematic review. 6 The following databases were searched without restrictions: Pubmed, EMBASE, the Cochrane Central Register, the ProQuest Medical Library, the EBSCOhost Online Research Databases, the Web of Science, and the Database of Abstracts of Reviews of Effects (DARE). In addition, the reference lists of important studies and reviews were hand-searched. Available abstracts and oral communications from conferences of the American Society of Hematology, the American Society of Clinical Oncology, and the European Hematology Association were also reviewed. Reference lists of relevant reviews and studies were searched manually. The last literature search was on November 12, 2018. Similar keywords were used in different databases: "isocitrate dehydrogenase inhibitor 1" or "inhibitor of mutant isocitrate dehydrogenase 1" or "IDH1 mutated" and "acute myeloid leukemia" [Mesh] and relapse or refractory or resistance or recurrence or recrudescence or "salvage therapy" or "salvage treatment".
The study selection was conducted by both authors independently. In cases of disagreement, a third reviewer (EB) adjudicated. Inclusion criteria were studies using IDH1 mut inhibitors in IDH1mut adult AML patients, especially in the subset of R/R AML, studies evaluating effectiveness and/or safety of IDH1 mut inhibitors in IDH1mut R/R AML, with at least CR rate or overall survival (OS), studies analyzing combinations of IDH1 mut inhibitors with other agents in R/R AML, and studies analyzing untargeted therapies that might be employed in the treatment of IDH1 mut R/R AML.
Our systematic search obtained 59 citations from databases and journals, and 19 records were identified through other sources (Figure 1 ). Of the 78 citations selected for full reading, 46 fulfilled the inclusion criteria and 22 were included. Agreement on study selection among the reviewers was excellent (kappa =0.97).
Data extraction
From the selected studies, we extracted data on study design, chemotherapy scheme, AML status, median age, CR, OS, and safety data. Different CR rates were reported in the included studies, including CR with incomplete blood count recovery (CRi), CR without platelet recovery (CRp), and CR with partial hematological recovery (CRh). Median CR duration (mCRD) is reported when data were available.
Diagnosis and epidemiology of
The IDH1 enzyme is encoded by the IDH1 gene on chromosome 2q33.3 and localized in the cytoplasm and peroxisomes. 3, 7, 8 The IDH1 gene normally encodes NADPH-dependent enzyme that catalyze the conversion of isocitrate to αKG. IDH1 mut reduces αKG to the oncometabolite D2HG, causing its accumulation. 3, 9, 10 Biochemical studies have shown that D2HG production can potentially affect epigenetic regulation and cell differentiation through inhibition of both histone and DNA demethylation.
11
In AML, the most frequently detected IDH1 mut is located in the Arg132 residue (R132), modifying the substrate-binding arginine of the enzyme catalytic domain for R132H, R132C, R132G, R132L, or R132S residues. The results of R132 IDH1 mut are hypermethylation of DNA and histones and a block in differentiation that implies the presence of leukemogenic myeloid progenitor cells. 7 Despite these effects, IDH mut enzymes alone do not cause leukemic transformation in mice. Several studies have demonstrated that IDH mutations tend to occur in combination with other mutations, suggesting cooperation to drive leukemogenesis in human AMLs. 12 Mutations in IDH1 and IDH2 are thought to be mutually exclusive, although occasionally in rare AML, patients have concurrent mutations in both IDH1 and IDH2.
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IDH1 epidemiology
Several studies have demonstrated that IDH1mut and IDH2 mut are associated with older age and confer an adverse prognosis, especially IDH1 mut in AML with a cytogenetically normal karyotype (CN-AML). 8, 14 Other covariants are associated with IDH1 mut , including intermediate-risk cytogenetics, a higher platelet count, increased bone marrow-blast percentage at diagnosis, FLT3-ITD and NPM1 mutations, 3, 8, 14, 15 and rarely related to therapy-related AML, TET2, and WT1 mutations. 
IDH1 comutations
A meta-analysis performed by Patel et al found that NPM1 is the most frequent concurrent mutation (87/144; 60.4%), followed by FLT3-ITD (37/146; 25.3%) and CEBPA (14/ 155; 9.0%). 18 In several studies, it has been shown that a heterogeneous pattern of certain gene mutations is associated with different prognostics. In CN-AML, a favorable genotype is defined by the association of NPM1 or CEBPA mutation without either FLT3-ITD nor IDH1 mutations. 16 Furthermore, IDH1 mutations confer adverse prognoses in CN-AML with NPM1 mutation without FLT3-ITD. 35 These associations were reproduced in the subset of CN-AML IDH1 mut patients. 34, 35 Furthermore, the IDH1 singlenucleotide polymorphism rs11554137 was also related to a poor OS. 35 The influence of these mutations in R/R AML remains scarcely reported. Mutation of IDH1 was an unfavorable factor for survival in a large cohort of 761 R/R AML treated with intensive salvage therapy. 36 The main schemes employed were based on a high dose of Ara-C (HiDAC), used in 71.2% of the patients. Unfortunately, specific data regarding the outcomes of IDH1 mut with each salvage scheme were not provided. The next large study analyzing the clinical outcomes of IDH mutations did not find any differences in the CR/CRi and the median OS (mOS) among IDH1 mut , IDH2 mut , and wild-type IDH (wtIDH) for AML induction or the first salvage therapy (S1) and the second or beyond salvage therapy (S2). This study employed at S1 and S2 schemes based on HiDAC (36% and 41%), hypomethylating agents (HMA) (32% and 27%), and low-dose Ara-C (24% and 3%). Specifically, IDH1 mut showed a CR/CRi of 40% vs 41%
and 36% vs 27% at S1 and S2 against wtIDH, respectively, and a mOS of 5.9 and 7.7 months at S1 and 4.0 and 4.8 months at S2, respectively. 3 Lower survival rates were reported in a French cohort of 185 R/R AML patients treated with standard salvage therapies (intensive chemotherapy in 68%, azacitidine in 18%, and other therapies in 14%) comparing IDH1 mut versus wtIDH and IDH2 mut (mOS 5.9, 7.6, and 11 months; 3-year OS 8%, 19%, and 23%), whereas no differences were reported in CR (50%, 43%, and 52%, respectively). 4 Recently, the outcomes of R/R AML with IDH1 mut from the UK NCRI AML trials treated with nontargeted therapy were analysed, showing mOS of 4.4 months, 1-year OS of 32%, 2-year OS of 17%. and remission rate of 23%. Age and AML subtypes (refractory, relapsed post-HSCT, second relapse, and relapsed within 1 year of remission) were not associated with differences in survival rates.
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Novel approaches in IDH1-mutated relapsed or refractory AML 40 The selected oral dose was 500 mg/24 hrs (maximum tolerated dose was not reached). It was rapidly absorbed (median 3 hrs to peak plasma concentration) and a steady state reached at 14 days. The steady-state mean apparent volume of distribution was 234 L and the protein bound was near 92-96%. CYP3A4 was the main way of metabolism, although 77% was excreted unchanged in the feces and 17% in the urine (10% unchanged), obtaining a clearance of 4.3 L/hr and a terminal elimination half-life of 93 hrs. 38 Table 1 ). The primary endpoint of this study, CR or CRh, was achieved in 30.2% for an mCRD of 6.5 months (31.8% and 8.2 months at the second cutoff). In addition, the CR rate was 21.8% with an mCRD of 9.3 months (24.0% and 10.1 months at second cut-off) and overall response (OR) of 39.1% and mCRD of 6.5 months (41.9% and 6.5 months at second cutoff). The mOS in the first primary efficacy cohort of 125 patients treated with 500 mg/24 hrs was 8.8 and 9.0 months after a median follow-up of 14.8 and 15.3 months. Transfusion independence ≥56 days was achieved in 35% of patients with previous transfusion dependence and maintained in 56% of the patients who were transfusion-independent at baseline.
After ivosidenib therapy, 21% IDH1 mut clearance was detected using digital PCR among the 34 patients who had CR or CRh 38 (23%, 11 of 47 at the second cutoff). 39 This subset of patients showed longer CRD (11.1 vs 6.5 months) and mOS (14.5 vs 10.2 months) than those without IDH1 mut clearance. The role of the baseline comutated genes was also evaluated, and a significant association between CR or CRh and a lower comutational burden was found (P=0.02). However, no specific preexisting mutations were identified as predictors of CR or resistance, although mutations in receptor tyrosine-kinase pathway genes were enriched in patients without response. 38 
Safety
Ivosidenib monotherapy of 500 mg/24 hrs in R/R AML had acceptable tolerance and was not related to any doselimiting toxic effects, although adverse events (AEs) were reported in 99% of the patients enrolled in Phase I clinical trial and the dose-expansion study [NCT02074839].
38,39 Table 1 summarizes the AEs reported in >20% patients in all the grades, as well as AE grades ≥3. Treatmentrelated AEs from ivosidenib were IDH differentiation syndrome (IDH-DS), prolongation of the QT interval, and leukocytosis. All these AEs are manageable and reversible, without needing permanent discontinuation of treatment. There were no deaths related to ivosidenib dose of 500 mg/24 hrs, whereas at 800 mg/24 hrs one AE-related death (cardiac tamponade) was reported as possibly associated with ivosidenib. IDH-DS is a potentially fatal AE that produces a rapid increase in the differentiation of neutrophils after the removal of the differentiation block in the malignant myeloid clone. It was initially described in acute promyelocytic leukemia and it is a common AE of IDH mut inhibitors. Thrombocytopenia (26) Febrile neutropenia (23) Anemia (19) Pneumonia (13) Neutropenia (7) Hypokalemia (7) Pyrexia (7) Leukocytosis (6) IDH Febrile neutropenia (62) Hypophosphatemia (13) Hypokalemia (10) Colitis (10) Hypertension (10) Bilirubin increased (7) Lung infection (5) Sepsis ( Thrombocytopenia (26) Febrile neutropenia (23) Anemia (19) Pneumonia (13) Neutropenia (7) Hypokalemia (7) Pyrexia (7) Leukocytosis (6) IDH-DS: 3 (11) Prolong QT interval: 1
AEs in >5% patients G
Febrile neutropenia (27) Anemia (19) Thrombocytopenia (19) Leukocytosis (19) Fatigue (15) Hypertension (15) Neutropenia (15) Nausea (12) Pneumonia (12) Hypokalemia (12) Abdominal pain (8) IDH-DS: 3 (13)
Notes: OS and CR has been estimated in months in the cases that it was reported in days (1 month =30 days) and weeks (1 month =4.3 weeks). 
Abbreviations:
≥2 nd R, second or beyond relapse; AML, acute myeloid leukemia; ALT, alanine aminotransferase; Ara-C, cytarabine; AST, aspartate aminotransferase; AZA, azacitidine; CR, complete remission; CRh, complete remission with partial hematologic recovery; CRi, complete remission with incomplete recovery; CRp, complete remission without platelet recovery; DNR, daunorubicin; ECOG-PS, Eastern Cooperative Oncology Group performance-status; EFS, event-free survival; ENA, enasidenib; ER, early relapse <1 year; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplantation; IDA, idarubicin; IDH, isocitrate dehydrogenase; IDH1 mut , isocitrate dehydrogenase 1 mutated;
IDH-DS, IDH differentiation syndrome; IVO, ivosidenib; LR, late relapse >1 year; MC, multicenter; mCRD, median CR duration; mDFS, median disease-free survival; MDS, myelodysplastic syndrome; MLFS, morphologic leukemia-free state; mOS, median overall survival; MRD, measurable residual disease; N, population of the cohort; NA, not available; NE, could not be estimated; OR, overall response; OS, overall survival; PROSP, prospective study; R, relapse; RCT, randomized clinical trial; RETROSP, retrospective study; RF, refractory; RFS, relapse-free survival; sAML, secondary AML; UC, unicentric or single center; y, year.
is worth noting that a new international Phase III randomized clinical trial aiming to enroll a large number of patients will compare AZA+IVO vs AZA in newly diagnosed IDH1 mut patients unfit for intensive chemotherapy 
Efficacy
The first set of data of the Phase I/II clinical trial was recently presented, including 31 patients treated with FT-2102 as a single agent with a median of 3 months (range 0.2-20 months), 22 of them with R/R AML with no prior therapy with IDH1 mut inhibitors (Table 1) . 53 Preliminary endpoints reported were CR rate of 14%, a CRi and morphologic leukemia-free state (MLFS) of 19%, and OR of 33%.
Safety
Regarding the safety of olutasidenib, severe AEs occurring in >5% of patients of the entire cohort are included in Table 1 . IDH-DS was reported in 3 patients and resolved after temporary discontinuation and treatment with dexamethasone, hydroxyurea, and supportive care. There were no deaths related to FT-2102 therapy. 53 
Future directions
Combinations of HMA and IDH mut inhibitors are being evaluated in several clinical trials because this combination increases hemoglobinization and the expression of erythroid differentiation markers, reduces leukemic stem cell populations, and potentiates apoptosis. (PARP inhibitor) combined with temozolomide in glioma, but these agents have not been tested in R/R AML yet.
IDH1-peptide vaccine
The mutation-specific vaccination of IDH1 (R132H) has been tested as a novel target for immunotherapy in glioma, as this neoantigen shows high uniform expression and penetrance in glioma cells. Preclinical studies in mice with IDH1-peptide vaccination obtained an effective mutation-specific antitumour immune response against IDH1
R132H
-expressing tumor cells and reduced the growth of gliomas. 70, 71 
